Concert Pharma (CNCE) Misses Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Boeing nears approval of 737 MAX anti-ice fix, paving way for deliveries
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
May 5, 2022 7:00 AM EDTPhase 3 Data Readout in Alopecia Areata Expected Second Quarter of 2022
Alopecia Areata Represents Significant Market Opportunity with Important Medical Need
Conference Call Scheduled Today at 8:30 a.m. ET
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ:... More
